Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Biomarkers in Oncology | Access & Reimbursment | US | NSCLC, Bladder Cancer, and Gastric / GEJ Adenocarcinoma | 2021
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is…